Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

NCT02263508 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02263508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02263508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Terminated
Start date
December 8, 2014
Completion date
March 11, 2021
Enrollment
713 (actual)
Sites
161

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma